GSK’s ViiV, Shionogi Settle Lupin Patent Suit on Juluca HIV Drug

GlaxoSmithKline PLC’s ViiV Healthcare and Shionogi & Co. settled a lawsuit alleging Lupin Ltd.’s proposed generic version of Juluca infringes two patents for the HIV-1 treatment, according to a court filing.

“Except as specifically authorized,” Lupin is blocked from making or selling Juluca copies until the patents have expired, according to a proposed consent judgment and order for dismissal filed Thursday in the U.S. District Court for the District of Delaware.

The dismissal, once approved, will terminate the 30-month regulatory stay of the U.S. Food and Drug Administration’s approval of Lupin’s generic version, the filing says.

ViiV and Shionogi—which owns ...